Drug intelligence / Profile preview

Nanotax

Development stage
Unknown
Lead developer
NanOlogy
Modality
Nanoparticles → Drug Delivery Systems, Small Molecules
Administration
Intraperitoneal
01

Overview

Nanotax is a nanoparticle formulation of the taxane chemotherapy agent paclitaxel, developed by CritiTech using its proprietary supercritical fluid precipitation technology. Unlike conventional paclitaxel formulations such as Taxol, which require surfactants like Cremophor EL and ethanol for solubility, Nanotax consists of pure paclitaxel particles in the nanometer range. This formulation is specifically designed for intraperitoneal (IP) administration to treat peritoneal neoplasms, including those originating from ovarian, colorectal, and gastric cancers. By delivering the drug directly into the peritoneal cavity, Nanotax aims to achieve high local concentrations of the active agent while minimizing systemic exposure and associated toxicities, such as hypersensitivity reactions and peripheral neuropathy, thereby potentially improving the therapeutic index for patients with refractory peritoneal malignancies.

Brand names
Nanotax
Other names
Nanoparticle paclitaxelIntraperitoneal nanoparticle paclitaxelIP Nanoparticle Paclitaxel
02

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on Nanotax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanotax.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call